Skip to main content

Table 1 Comparison of clinicopathological findings by existence of liver metastases

From: Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival

   Patients with liver metastases n = 69 (cases) Patients without liver metastases n = 70 (cases) pvalue
Gender M/F 40/29 38/32 N.S.
Age Years 60.7 ± 9.9 62.5 ± 10.1 N.S.
TNM stage I/II/III/IV 0/12/23/34 11/38/21/0 < 0.01a
Tumour site C/R 45/24 49/21 N.S.
LN mets Yes/No 41/28 31/39 N.S.
Differentiation w/mod/por 37/30/2 21/33/16 N.S.
Liver mets Sync/Meta 23/46 N.A. N.A.
No. of liver mets Solo/Multi 38/31 N.A. N.A.
PTEN expression S/W 17/52 44/26 < 0.01a
Median follow-up Months 35.5 ± 27.4 37.2 ± 39.9 N.S.
5-year survival (%) 34.3 79.2 < 0.01b
  1. LN, lymph node; mets, metastasis; M, male; F, female; C, colon; R, rectum; w, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; por, poorly differentiated adenocarcinoma; Sync, synchronous metastasis; Meta, metachronous metastasis; Solo, solitary metastasis; Multi, multiple metastases; S, strong; W, weak; N.A., not applicable; N.S., not significant. The a p-values were obtained using the Mann-Whiteny U test. The b p-values were obtained using Kaplan-Meier survival curves based on PTEN expression tested with the Wilcoxon test. Values of age are given mean ± s.d. N.S., not significant.